Trial Profile
A multicenter, four arm, randomized, open label clinical study investigating optimized dosing in a Prograf/Advagraf-based immunosuppressive regimen in kidney transplant subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Basiliximab; Methylprednisolone; Mycophenolate mofetil; Prednisone
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms OSAKA
- Sponsors Astellas Pharma
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 01 Nov 2017 Results of pooled analysis of NCT00189839 and NCT00717470 trials comparing outcomes with prolonged-release tacrolimus and immediate-release tacrolimus published in the Transplantation Proceedings
- 12 Jul 2014 EudraCT reports trial as recruiting in France, Spain, United Kingdom and Slovakia and completed in remaining countries; status retained as per NCT as it is recently updated..